T Time: Women Were First to Put Testosterone Back on FDA’s Agenda. Now It’s Industry’s Turn September 23, 2026 By Sarah Wicks —

https://www.thefdalawblog.com/2026/09/t-time-women-were-first-to-put-testosterone-back-on-fdas-agenda-now-its-industrys-turn/?utm_source=rss&utm_medium=rss&utm_campaign=t-time-women-were-first-to-put-testosterone-back-on-fdas-agenda-now-its-industrys-turn More than two decades after FDA last publicly grappled with the development of testosterone for women, the Agency is asking industry to take another look. On September 17, 2026, FDA’s Office of Women’s Health (OWH) and the Center for Drug Evaluation and Research (CDER) convened a public workshop on testosterone use in menopausal women. The day-long meeting brought together clinicians, researchers, patients, and FDA officials to discuss what is known, what remains unknown, and, importantly for drug developers, what it may take to develop an FDA-approved testosterone product for women.